Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 261

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial

Open access
Xu, Jie, Wang, Anxin, Meng, Xia, Yalkun, Gulbahram, Xu, Anding, Gao, Zhiqiang, Chen, Huisheng, Ji, Yong, Xu, Jun, Geng, Deqin, Zhu, Runxiu, Liu, Bo, Dong, Aiqin, Mu, Hua, Lu, Zhihong, Li, Shuya, Zheng, Huaguang, Chen, Xia, Wang, Yilong, Zhao, Xingquan, Wang, Yongjun, Wang, Yongjun, Xu, Anding, Zhao, Xingquan, Chen, Xia, Wang, Yongjun, Meng, Xia, Wang, Yilong, Xu, Jie, Wang, Anxin, Zheng, Huaguang, Gao, Zhiqiang, Duan, Lei, Zhang, Jinghua, Li, Shuya, Lou, Donghua, Gao, Zhiqiang, Chen, Huisheng, Ji, Yong, Xu, Jun, Geng, Deqin, Zhu, Runxiu, Liu, Bo, Dong, Aiqin, Liang, Qingcheng, Yang, Hong, Guo, Cunju, Li, Xin, He, Mingli, Tian, Xiangyang, Cui, Yong, Zhou, Junshan, Wang, Ning, Wang, Lei, Zhang, Xinjiang, Gao, Xiaoping, Lu, Liping, Li, Tong, Cheng, Yan, Liu, Kaixiang, Xi, Xiaokun, Wang, Baojun, Sun, Lin, Zhao, Shigang, Chu, Xiaofan, Lian, Yajun, Yan, Fuling, Wang, Xiaoshan, Wang, Dong, Shao, Bei, Jiao, Jinsong, Wu, Heng, Li, Guanglai, Guo, Libin, Wang, Yongjun, Pan, Suyue, Xu, Anding, Li, Heng, Zhuang, Jianhua, Li, Xin, Wu, Jun, Wang, Anxin, Lou, Donghua, Zuo, Yingting, Zhang, Yijun, Zhang, Xiaoli, Feng, Xiaofei, Meng, Xia, Wang, David, Dong, Kehui, Liu, Yanfang, Li, Hao, Chen, Dawei, Lv, Qiushi · 2021 · Stroke

Abstract

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12–1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49–3.43 versus 1.14, 0.85–1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02430350.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/strokeaha.120.031197

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 261

Metadata

Authors
Xu, J., Wang, A., Meng, X., Yalkun, G., Xu, A., Gao, Z., Chen, H., Ji, Y., Xu, J., Geng, D., Zhu, R., Liu, B., Dong, A., Mu, H., Lu, Z., Li, S., Zheng, H., Chen, X., Wang, Y., Zhao, X., Wang, Y., Wang, Y., Xu, A., Zhao, X., Chen, X., Wang, Y., Meng, X., Wang, Y., Xu, J., Wang, A., Zheng, H., Gao, Z., Duan, L., Zhang, J., Li, S., Lou, D., Gao, Z., Chen, H., Ji, Y., Xu, J., Geng, D., Zhu, R., Liu, B., Dong, A., Liang, Q., Yang, H., Guo, C., Li, X., He, M., Tian, X., Cui, Y., Zhou, J., Wang, N., Wang, L., Zhang, X., Gao, X., Lu, L., Li, T., Cheng, Y., Liu, K., Xi, X., Wang, B., Sun, L., Zhao, S., Chu, X., Lian, Y., Yan, F., Wang, X., Wang, D., Shao, B., Jiao, J., Wu, H., Li, G., Guo, L., Wang, Y., Pan, S., Xu, A., Li, H., Zhuang, J., Li, X., Wu, J., Wang, A., Lou, D., Zuo, Y., Zhang, Y., Zhang, X., Feng, X., Meng, X., Wang, D., Dong, K., Liu, Y., Li, H., Chen, D., & Lv, Q.
Venue
Stroke
Published
2021-03
Volume
52
Issue
3
Pages
772-780
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W3129319285
Cited by
261
References
30
FWCI
19.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.